Gilead Sciences, Inc. vs Regeneron Pharmaceuticals, Inc.: Strategic Comparison

This in-depth comparison examines Gilead Sciences, Inc. and Regeneron Pharmaceuticals, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Gilead Sciences, Inc. on its own, evaluating Regeneron Pharmaceuticals, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Gilead Sciences, Inc. and Regeneron Pharmaceuticals, Inc. is widest.

On the headline numbers, annual revenue is $29.4B (FY2025) for Gilead Sciences, Inc. and $14.3B (FY2025) for Regeneron Pharmaceuticals, Inc., while their respective market capitalizations stand at $180.0B and $75.0B. Both Gilead Sciences, Inc. and Regeneron Pharmaceuticals, Inc. are headquartered in United States. Their local markets and applicable rules may still differ.

Gilead Sciences, Inc.: Gilead Sciences is one of the largest US biotechnology companies, with about 17,000 employees and a market value near $180B in September 2026. It turned HIV into a manageable chronic disease with tenofovir-based medicines, cured most hepatitis C patients with Sovaldi and Harvoni, and supplied the first approved COVID-19 antiviral, Veklury. Today HIV accounts for roughly 71% of revenue, with oncology and liver disease making up most of the rest. The company is headquartered in Foster City, California.

Regeneron Pharmaceuticals, Inc.: Regeneron is a Tarrytown, New York biotech that discovers, develops and manufactures its own biologic medicines. Its best-known products are EYLEA and EYLEA HD for retinal disease, Dupixent (with Sanofi) for eczema, asthma, COPD and other Type 2 inflammatory conditions, and Libtayo for cancer. Co-founders Leonard Schleifer (CEO) and George Yancopoulos (Chief Scientific Officer) still lead the company, which had about 15,400 employees at the end of 2025. Regeneron was founded in 1988 in New York City by Dr. Leonard Schleifer and Dr. George Yancopoulos, establishing its primary laboratories in Tarrytown, New York, and pioneering the proprietary VelociSuite genetics platform to build one of the world’s most scientifically productive biopharmaceutical giants.

Gilead Sciences, Inc. and Regeneron Pharmaceuticals, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Gilead Sciences, Inc. and Regeneron Pharmaceuticals, Inc..

Gilead Sciences, Inc. business model: Gilead discovers, licenses or acquires drug candidates, takes them through clinical trials and regulatory approval, then sells them through wholesalers, pharmacies and hospitals under patent protection. Product sales were $28.9B of FY2025 revenue, with the rest coming from royalties and contract income. HIV is the profit engine: Biktarvy is a once-daily single tablet that patients typically take for years, which makes revenue recurring. Non-GAAP product gross margin was 86.4% in 2025, and Gilead spent $5.8B on R&D plus about $1.0B on acquired in-process R&D. Large acquisitions such as Pharmasset (2011), Kite (2017), Immunomedics (2020), CymaBay (2024) and Arcellx (2026) have supplied most of its new franchises.

Regeneron Pharmaceuticals, Inc. business model: Regeneron makes money three ways. First, it records U.S. net product sales of its own medicines, mainly EYLEA HD and EYLEA for retinal disease, Libtayo in oncology, and smaller rare-disease products. Second, it earns collaboration revenue from Sanofi on Dupixent and Kevzara: Sanofi books global sales and the two companies share profits. Third, it shares ex-U.S. EYLEA profits with Bayer, which sells the drug outside the United States. The discovery engine behind all of this is VelociSuite, including VelocImmune mice that produce fully human antibodies.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Gilead Sciences, Inc. stack up against those of Regeneron Pharmaceuticals, Inc..

Gilead Sciences, Inc. competitive advantage: Gilead's moat is three decades of antiviral chemistry and HIV clinical data. Tenofovir-based backbones, Biktarvy's single-tablet convenience and a high barrier to resistance made it the most prescribed HIV regimen in the US, and lenacapavir gave Gilead the first twice-yearly HIV prevention injection (Yeztugo, FDA approved June 2025). Its scale in HIV sales and payer contracting, plus about $10.6B of cash and marketable securities at the end of 2025, lets it fund acquisitions without depending on one deal.

Regeneron Pharmaceuticals, Inc. competitive advantage: Regeneron's edge is an in-house discovery platform (VelociSuite and VelocImmune) paired with the Regeneron Genetics Center's large human-sequencing dataset, which helps pick drug targets with genetic validation. Its two founders still run the company, so R&D priorities have stayed consistent for more than three decades, and it manufactures its own biologics in Rensselaer, New York and Limerick, Ireland.

Future prospects matter as much as current results. The growth strategies below explain how Gilead Sciences, Inc. and Regeneron Pharmaceuticals, Inc. each plan to expand from here.

Gilead Sciences, Inc. growth strategy: Gilead's growth plan has four parts: expand HIV prevention with Yeztugo and Descovy, defend HIV treatment with next-generation regimens such as bictegravir/lenacapavir, grow liver disease with Livdelzi, and buy into oncology and inflammation. In 2025 it acquired Interius BioTherapeutics for in vivo CAR-T. In 2026 it closed Arcellx (about $7.8B implied equity value), Tubulis ($3.15B upfront, up to $1.85B in milestones) and Ouro Medicines ($1.675B upfront, with Lakefront) to rebuild its pipeline.

Regeneron Pharmaceuticals, Inc. growth strategy: Regeneron is defending ophthalmology with EYLEA HD (8 mg aflibercept, longer dosing intervals), widening Dupixent into new Type 2 inflammatory indications such as COPD, and building oncology and hematology around Libtayo and bispecifics such as linvoseltamab and odronextamab. It is also adding modalities through gene editing with Intellia, siRNA medicines with Alnylam, gene therapy from the Decibel deal and cell therapy through Regeneron Cell Medicines.

A closer look at the financial trajectory of Gilead Sciences, Inc. and Regeneron Pharmaceuticals, Inc. rounds out the comparison.

Gilead Sciences, Inc.: Gilead's revenue history tracks its product cycles. Hepatitis C cures Sovaldi and Harvoni lifted revenue to $30.4B in 2016, then sales fell as patients were cured, bottoming at $22.1B in 2018. HIV growth and pandemic Veklury sales took revenue back to $27.3B in 2021, and it has since grown slowly to $28.8B in 2024 and $29.4B in 2025. Net income swings with deal accounting: it was only $480M in 2024 because of the CymaBay IPR&D charge, then recovered to $8.5B ($6.78 diluted EPS) in 2025. In Q2 2026 revenue rose 10% to $7.8B, but more than $11B of acquired IPR&D, mainly from Arcellx, produced a GAAP loss of $8.45 per share. February 2026 guidance called for $29.6B to $30.0B in 2026 product sales. Gilead Sciences, Inc. is a massive American biopharmaceutical company, commanding a market valuation typically over $80 billion.

Regeneron Pharmaceuticals, Inc.: Regeneron's revenue rose from $4.86 billion in 2016 to $16.07 billion in 2021, inflated by COVID-19 antibody sales, then reset to $12.17 billion in 2022. It has since grown slowly: $13.12 billion in 2023, $14.20 billion in 2024 and $14.34 billion in 2025, as Dupixent gains offset lower original EYLEA sales. Growth picked up in 2026, with Q2 revenue up 17% to $4.3 billion, GAAP EPS of $12.23 and non-GAAP EPS of $14.29. Regeneron Pharmaceuticals, Inc. is a colossal American biotechnology company specializing in antibody therapeutics, sustaining a massive market valuation generally exceeding $100 billion.